RecruitingNCT04053855

Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Enrollment

100 participants

Start Date

Jan 29, 2020

Study Type

OBSERVATIONAL

Conditions

Clear Cell Renal Cell Carcinoma

Summary

Clear cell renal cell carcinoma is diagnosed by imaging, sometimes associated with biopsy. This diagnosis is expensive, invasive and sometimes late. The development of a simple biological test for diagnosis is essential. Exosomes are 30 to 150 nm membrane vesicles secreted into the extracellular space by various living cells. These exosomes can be isolated from biological fluids, including urine. The recent study of urinary exosomes is a promising topic for analyzing tumor markers in urine. The investigator's goal is to develop a reliable technique for detecting tumor exosomes in urine in patients with clear cell renal cell carcinoma. The analysis of urinary exosomes could provide a new liquid biopsy tool for the early diagnosis of clear cell renal cell carcinoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study investigates whether tiny particles called exosomes in urine can be used to detect and monitor clear cell renal cell carcinoma (a type of kidney cancer). Urine-based tests could eventually offer a non-invasive way to diagnose or track kidney cancer without surgery or invasive biopsies. **You may be eligible if...** - You are a patient with a kidney mass requiring surgery (partial or total kidney removal) - You are affiliated with the French social security system and have signed informed consent - (As a control): You are having a nephrectomy for non-cancer reasons **You may NOT be eligible if...** - Your urine sample volume is insufficient (less than 100 ml) - You require a urinary catheter - You are under legal guardianship Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALUrinary sample

Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.

Locations(1)

Chu Saint-Etienne

Saint-Etienne, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04053855

Related Trials

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

NCT06661720410 locations

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

NCT056637101 location

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

NCT0553614125 locations

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

NCT070370042 locations

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT0722741549 locations